277 related articles for article (PubMed ID: 33057153)
1. Pan-cancer driver copy number alterations identified by joint expression/CNA data analysis.
Wang G; Anastassiou D
Sci Rep; 2020 Oct; 10(1):17199. PubMed ID: 33057153
[TBL] [Abstract][Full Text] [Related]
2. CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications.
Franch-Expósito S; Bassaganyas L; Vila-Casadesús M; Hernández-Illán E; Esteban-Fabró R; Díaz-Gay M; Lozano JJ; Castells A; Llovet JM; Castellví-Bel S; Camps J
Elife; 2020 Jan; 9():. PubMed ID: 31939734
[TBL] [Abstract][Full Text] [Related]
3. Detection of candidate tumor driver genes using a fully integrated Bayesian approach.
Yang J; Wang X; Kim M; Xie Y; Xiao G
Stat Med; 2014 May; 33(10):1784-800. PubMed ID: 24347204
[TBL] [Abstract][Full Text] [Related]
4. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.
Both J; Krijgsman O; Bras J; Schaap GR; Baas F; Ylstra B; Hulsebos TJ
PLoS One; 2014; 9(12):e115835. PubMed ID: 25551557
[TBL] [Abstract][Full Text] [Related]
5. Specific genomic regions are differentially affected by copy number alterations across distinct cancer types, in aggregated cytogenetic data.
Kumar N; Cai H; von Mering C; Baudis M
PLoS One; 2012; 7(8):e43689. PubMed ID: 22937079
[TBL] [Abstract][Full Text] [Related]
6. ProcessDriver: A computational pipeline to identify copy number drivers and associated disrupted biological processes in cancer.
Baur B; Bozdag S
Genomics; 2017 Jul; 109(3-4):233-240. PubMed ID: 28438487
[TBL] [Abstract][Full Text] [Related]
7. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning.
Zhou W; Zhao Z; Wang R; Han Y; Wang C; Yang F; Han Y; Liang H; Qi L; Wang C; Guo Z; Gu Y
Mol Oncol; 2017 Oct; 11(10):1459-1474. PubMed ID: 28719033
[TBL] [Abstract][Full Text] [Related]
8. Probability distribution of copy number alterations along the genome: an algorithm to distinguish different tumour profiles.
Esteves L; Caramelo F; Ribeiro IP; Carreira IM; de Melo JB
Sci Rep; 2020 Sep; 10(1):14868. PubMed ID: 32913269
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
11. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.
Graham NA; Minasyan A; Lomova A; Cass A; Balanis NG; Friedman M; Chan S; Zhao S; Delgado A; Go J; Beck L; Hurtz C; Ng C; Qiao R; Ten Hoeve J; Palaskas N; Wu H; Müschen M; Multani AS; Port E; Larson SM; Schultz N; Braas D; Christofk HR; Mellinghoff IK; Graeber TG
Mol Syst Biol; 2017 Feb; 13(2):914. PubMed ID: 28202506
[TBL] [Abstract][Full Text] [Related]
12. Identification of druggable cancer driver genes amplified across TCGA datasets.
Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing somatic and germline copy number events in cancer patient DNA hybridized to whole-genome SNP genotyping arrays.
Ha G; Shah S
Methods Mol Biol; 2013; 973():355-72. PubMed ID: 23412801
[TBL] [Abstract][Full Text] [Related]
14. The repertoire of copy number alteration signatures in human cancer.
Tao Z; Wang S; Wu C; Wu T; Zhao X; Ning W; Wang G; Wang J; Chen J; Diao K; Chen F; Liu XS
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36806386
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide somatic copy number alteration analysis and database construction for cervical cancer.
Luo H; Xu X; Yang J; Wang K; Wang C; Yang P; Cai H
Mol Genet Genomics; 2020 May; 295(3):765-773. PubMed ID: 31901979
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
17. The shaping and functional consequences of the dosage effect landscape in multiple myeloma.
Samur MK; Shah PK; Wang X; Minvielle S; Magrangeas F; Avet-Loiseau H; Munshi NC; Li C
BMC Genomics; 2013 Oct; 14():672. PubMed ID: 24088394
[TBL] [Abstract][Full Text] [Related]
18. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer.
Zhang L; Yuan Y; Lu KH; Zhang L
BMC Bioinformatics; 2016 May; 17(1):222. PubMed ID: 27230211
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide identification of significant aberrations in cancer genome.
Yuan X; Yu G; Hou X; Shih IeM; Clarke R; Zhang J; Hoffman EP; Wang RR; Zhang Z; Wang Y
BMC Genomics; 2012 Jul; 13():342. PubMed ID: 22839576
[TBL] [Abstract][Full Text] [Related]
20. Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.
Khalil AIS; Khyriem C; Chattopadhyay A; Sanyal A
BMC Bioinformatics; 2020 Apr; 21(1):147. PubMed ID: 32299346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
